Advertisement
Advertisement
TOPIC

Biomedicine: Policy

Related Topics:
Biomedicine: Policy
Learn about China’s biomedical breakthroughs, from cutting-edge pharmaceuticals to life-saving research, driving global health innovation.
The cost advantages of Chinese pharmaceuticals mean they still appeal to multinational drug makers despite US security concerns. Photo: TNS
China’s private sector

Chinese pharmaceutical firms’ cost advantages trump Pentagon blacklist: analysts

Growing collaboration between multinational drug makers and Chinese companies not expected to slow after US move.

China’s private sector

Akeso lung cancer drug trial raises hopes in US$20b market

China manufacturing

China extols potential of AI in guideline on marine biopharmaceuticals

Biomedicine: Companies

China’s Innovent Biologics signs US$10.5b Pfizer deal for 12 cancer drug trials

The agreement covers eight early-stage trials from Innovent and four discovery programmes from global giant Pfizer.

videocam
A researcher uses a microscope in a cancer research laboratory. Photo: Shutterstock
China’s private sector

China’s biotech boom drives surge in home-grown innovative drug approvals

Domestic firms dominate China’s drug approvals amid jump in spending and out-licensing deals as regulator speeds path to market.

US-China relations

As I see it | US’ scientific self-harm will only help China

While Washington slashes funding for the sciences, Beijing is clinching its lead in everything from patent applications to publications.

videocam
16
Advertisement
Advertisement
Advertisement
China’s private sector

China’s Hengrui seals US$15.2 billion deal with US pharmaceutical giant BMS

Company’s shares jump in Hong Kong and Shenzhen after tie-up that bolsters China’s growing drug innovation profile.

A worker checks a feeding tray at the Hengrui Biomedical Industrial Park in Lianyungang, east China’s Jiangsu province. Photo: Getty Images
China’s private sector

How China’s ‘landmark’ drug pricing guidelines could be a boon for biotech

State Council calls for ‘value-based pricing’ for innovative drugs, a move researchers said would benefit private healthcare players.

China’s private sector

China’s drug makers are speeding up – will AI be their secret weapon?

Chinese biotech firms are striking big global deals as drug makers, but could artificial intelligence take them to the next level?

Biomedicine: Companies

Global drug makers face pricing pressure as China targets affordable healthcare

As pharmaceutical firms navigate China’s aggressive pricing reforms, their profits could be squeezed further this year.

5
A pharmaceutical production line in Meishan, China. Photo: Costfoto/NurPhoto via Getty Images
Banking & finance

Chinese company to use AI-powered testing to boost profits and fast-track IVF

China’s falling fertility rate sees spike in demand for assisted reproduction as biotech firm raises US$101 million from Hong Kong listing.

videocam
A Chinese biotech company is hoping AI technology will help to boost profits and speed up chromosome testing which is a vital part of In vitro fertilisation. Photo: Dreamstime/TNS
China’s private sector

China’s obesity drug makers take on global giants as Novo Nordisk patent expires

Patent expiry of blockbuster drug opens door for Chinese drug makers to challenge multinationals in booming weight-loss market.

Banking & finance

Hong Kong attracts wave of biotech IPO filings amid AI drug research boom

More than 10 pre-profit drug developers are seeking Hong Kong listings as AI-powered biotech platforms draw growing investor interest.

Biomedicine: Companies

In a first for China, Neuracle’s brain-computer interface wins approval

China’s BCI start-ups, seen as potential rivals to Elon Musk’s Neuralink, gain momentum as regulatory support and new capital fuel growth.

A man demonstrates a robotic hand with a brain-computer interface at the China International Import Expo on November 7, 2025. Neuracle’s regulatory milestone underscores China’s accelerating push in neurotechnology. Photo: AFP
Banking & finance

China investors energise Hong Kong biotech stocks. Is foreign money missing out?

Stock Connect reshuffle reflects biotech sector’s growing role on international stage, though overseas funds remain cautious.

Overseas capital tends to cherry-pick a few big-cap pharmaceutical companies rather than buy the biotech sector broadly, according to an analyst. Photo: Handout
Insilico

Insilico Medicine advances Middle East push with UAE AI drug discovery deal

Hong Kong-listed biotech firm’s shares jump after announcing partnership to use AI tools in drug discovery in the United Arab Emirates.

Two Sessions 2026

China and Hong Kong should relax biotech listing rules, venture capitalist says

Foreign investors are returning to China’s healthcare sector, but IPO bottlenecks and takeover rules could deter deals, VC Nisa Leung says.

Advertisement
Advertisement
Advertisement
Made in China 2025

China biotech outlicensing tops US$52 billion in first 2 months

The latest deals are Sino Biopharmaceutical’s partnership with France’s Sanofi and Antengene’s agreement with Belgium’s UCB.

The logo of Sino Biopharmaceutical is seen on a building in Beijing, April 22, 2021. Photo: VCG via Getty Images
Two Sessions 2026

Healthcare investors looking to ‘two sessions’ for clarity on drug pricing

Healthcare and insurance sectors will see policy fine-tuning, ‘moral support’ rather than ‘groundbreaking news’ from Beijing, analysts say.

China’s private sector

Biomedicine | China challenges US in new drugs after industry transformation

Drug makers in China are performing cutting-edge research and licensing products to global giants after a 10-year government push supercharged the industry.

Made in China 2025

Chinese biotechs strike a record US$136 billion in out-licensing deals in 2025

Chinese drug makers signed 157 out-licensing deals with global pharmaceutical firms last year versus 94 a year earlier.

Last year, China approved 76 innovative drugs, including 47 chemical drugs and 23 biologics. Photo: Shutterstock
Made in China 2025

China’s new drug insurance: lifeline for patients or squeeze on big firms?

New insurance formulary trims costs of Alzheimer’s and cancer therapies and marks a small win for global novel drug makers.

The commercial insurance formulary covers some medicines that are not yet eligible for reimbursement under the country’s National Reimbursement Drug List. Photo: Shutterstock
China economy

Opinion | How China engineered the rapid rise of its drug innovation industry

A market once dominated by generics is now an AI-powered pharmaceutical hub drawing billion-dollar investments from the likes of Pfizer and GSK.

videocam
Hong Kong healthcare and hospitals

Editorial | Hospital fee reform must balance social fairness with budgetary needs

While standard X-ray services at public hospitals will remain free, the pricing overhaul must be watched closely to avoid unintended harm.

Biomedicine: Industry Trends

China’s clinical trial capacity matches US, attracts more global pharma firms

Growth of innovative clinical trials suggests that Chinese biotech firms’ pipeline of novel drug candidates is expanding, analysts say.

China had 2,694 new clinical trials in 2024, up 13 per cent from a year earlier. Photo: Shutterstock
New medical drugs

6 of the best: the billion-dollar biotechs putting China on the map

China’s biotech renaissance is gathering pace as home-grown innovators strike billion-dollar licensing deals with global giants.

Illustration: Henry Wong
China’s private sector

‘Quantity to quality’: what China’s next 5-year plan means for foreign investors

Beijing has pledged to open up even more to foreign investment. But some officials are becoming more selective about the projects they want.

videocam
Biomedicine: Industry Trends

China’s drug developers stretch to become a global force

Although a start-up’s recent triumph is seen as a ‘DeepSeek moment’, domestic players still trail world-beating pharma firms, experts say.

10
Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement